Allogeneic cytomegalovirus-specific T cells therapy(Queensland Institute Of Medical Research)

N/A

Report date: 2024/04/23 17:57:43

Base Information

Drug NameAllogeneic cytomegalovirus-specific T cells therapy(Queensland Institute Of Medical Research)

Drug Alias NameAllogeneic cytomegalovirus [CMV]-specific T cells therapy(Queensland Institute Of Medical Research)CYT-101

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Virus-specific T Cell therapyCell and gene therapy > Cell therapy > Donor > Allogeneic

Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity

TargetsNot applicable

Therapy Area/IndicationsGlioblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustralia

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesCyteph Inc

China Registration ClassN/A

Develop Information

Active CompaniesQueensland Institute Of Medical Research

Inactive CompaniesN/A

Active IndicationsGlioblastoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A